Pharmazz Gains FDA Orphan Designation for Sovateltide in NHIE
WILLOWBROOK, Ill. — September 14, 2026 Pharmazz, Inc. announced that the U.S. Food and Drug Administration (FDA) Office of...
neuroprotection
Advertisement
Quantum BioPharma Advances Lucid-MS Into Phase 2
Toronto, Canada — August 14, 2026 Quantum BioPharma Ltd. reported continued progress on its lead therapeutic program Lucid-MS, following...
Oculis Acquires Privosegtor to Expand Neuro-Ophthalmology
Zug, Switzerland & Barcelona, Spain, August 10, 2026 Oculis Holding AG and Accure Therapeutics S.L. have entered into an...
Oculis Achieves Positive FDA Pre-IND Outcome for Privosegtor Program
ZUG, Switzerland, Aug. 3, 2026 Oculis announced that the U.S. Food and Drug Administration (FDA) has provided positive pre-Investigational...
Oculis Holding AG Secures FDA SPA for Privosegtor Optic Neuritis Phase 3 Trial
ZUG, Switzerland – May 7, 2026 Oculis Holding AG announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
InspireMD, Inc. Secures FDA IDE for CGUARDIANS III
MIAMI, May 1, 2026 InspireMD, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its...
LT3001 Stroke Drug Shows Phase 2 Functional Gains
Taipei, Taiwan — February 6, 2026 Lumosa Therapeutics has announced positive Phase 2 clinical trial outcomes for LT3001 (odatroltide),...
Government contract pursuit advances Halberd TBI nasal-spray program
JACKSON CENTER, Pa., November 3, 2025 — Halberd Corporation, in collaboration with Mississippi State University (MSU), announced continued efforts...
Oculis Highlights Late-Stage Eye Pipeline at AAO 2025
October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...
Advertisement
